Editor’s Pick – Characterising Drug-Associated Nephrolithiasis: Insights from Global Adverse Drug Reaction Database

• Published in: European Medical Journal (Chelmsford, England) pp. 72 - 82
• Main Authors: Baptista, Alexandre, Macedo, Ana, Marreiros, Ana, Coelho, André
• Format: Journal Article
• Language: English
• Published: 12.06.2025
• ISSN: 2397-6764; 2397-6764
• DOI: 10.33590/emj/UHEJ6955

Nojaba L, Guzman N. Nephrolithiasis (Kidney Stones) (Archived) [Internet] (2023) Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK559227/. Last accessed: 21 January 2024 Stamatelou K, Goldfarb DS. Epidemiology of kidney stones. Healthcare (Basel). 2023;11(3):424. Daudon M et al. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs. 2018;78(2):163-201. Hara M et al. Atazanavir nephrotoxicity. Clin Kidney J. 2015;8(2):137-42. Dong BJ et al. Sulfadiazine-induced crystalluria and renal failure in a patient with AIDS. J Am Board Fam Pract. 1999;12(3):243-8. Go T. Effect of antiepileptic drug polytherapy on crystalluria. Pediatr Neurol. 2005;32(2):113-5. Paul E et al. Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. Epilepsy Res. 2010;90(1-2):151-6. European Medicines Agency. Summary of product characteristics. 2025. Available from: https://www.ema.europa.eu/en/glossary/summary-product-characteristics. Last accessed: 21 January 2024 UpToDate. UpToDate. 2025. Available at: https://www.wolterskluwer.com/en-gb/solutions/uptodate. Last accessed: 21 January 2024 Drugs.com. Find Drugs & Conditions. 2025. Available at: https://www.drugs.com/. Last accessed: 21 January 2024 James ET, Douglas AM (eds.). Drug-induced diseases: prevention, detection, and management (2018) 3rd ed, Bethesda: American Society of Health-System Pharmacists. Ray SD (ed.), Side Effects of Drugs Annual 38 - A worldwide yearly survey of new data in adverse drug reactions (2016), Amsterdam: Elsevier. Ferraro PM et al. Factors associated with sex differences in the risk of kidney stones. Nephrol Dial Transplant. 2023;38(1):177-83. Gillams K et al. Gender differences in kidney stone disease (KSD): findings from a systematic review. Curr Urol Rep. 2021;22(10):50. Letavernier E, Daudon M. Vitamin D, hypercalciuria and kidney stones. Nutrients. 2018;10(3):366. Sakhaee K et al. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int. 2011;79(4):393-403 Yasui T et al. Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis. Urol Int. 2009;83(2):226-9. Wessels H et al. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial. Expert Opin Biol Ther. 2023;23(12):1287-97 Prochaska M. Bisphosphonates and management of kidney stones and bone disease. Curr Opin Nephrol Hypertens. 2021;30(2):184-9. Simonov M et al. Use of proton pump inhibitors increases risk of incident kidney stones. Clinical Gastroenterology and Hepatology. 2021;19(1):72-79.e21. Song YK et al. Potential adverse events reported with the janus kinase inhibitors approved for the treatment of rheumatoid arthritis using spontaneous reports and online patient reviews. Front Pharmacol. 2022;12:792877. Thorpy MJ et al. Efficacy and safety of lower-sodium oxybate in an open-label titration period of a phase 3 clinical study in adults with idiopathic hypersomnia. Nat Sci Sleep. 2022;14:1901-17. Abbott Laboratories. Humira Summary of Product Characteristics. 2003. Available at: https://ec.europa.eu/health/documents/community-register/2009/2009082865869/anx_65869_en.pdf. Last accessed: 25 May 2025 Adam A. Bilateral obstructive ureteral stones after using a dose of frozen adalimumab in a patient with Crohn’s disease. Am J Gastroenterol. 2018;113:S1651. Jakobsen AK et al. Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS One. 2014;9(11):e113602. Alameddine Z et al. Risk of nephrolithiasis in patients with inflammatory bowel disease receiving biologic treatment. J Clin Med. 2023;12(19):6114. European Medicines Agency. Remicade (infliximab). 2012. Available at: https://www.ema.europa.eu/en/documents/overview/remicade-epar-summary-public_en.pdf. Last accessed: 21 January 2024 Dimke H et al. Risk of urolithiasis in patients with inflammatory bowel disease: a nationwide Danish cohort study 1977–2018. Clin Gastroenterol Hepatol. 2021;19(12):2532-2540.e2. WyethLerderle. Etanercept - Resumo das Características do Medicamento. 2000. Available at: https://www.ema.europa.eu/en/documents/overview/enbrel-epar-summary-public_en.pdf. Last accessed: 25 May 2025 Tsevi YM et al. [Life-threatening hypercalcemia and acute kidney injury induced by etanercept]. Nephrol Ther. 2018;14(6):478-82. (In French) Schwartz BF et al. Imaging characteristics of indinavir calculi. J Urol. 1999;161(4):1085-7. Saltel E et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164(6):1895-7. Gagnon RF et al. Indinavir crystalluria. Kidney Int. 2006;70(12):2047. Fogo AB et al. AJKD atlas of renal pathology: indinavir nephrotoxicity. Am J Kidney Dis. 2017;69(1):e3. Garnier AS et al. High incidence of amoxicillin-induced crystal nephropathy in patients receiving high dose of intravenous amoxicillin. J Clin Med. 2020;9(7):2022. Joshi S, Goldfarb DS. The use of antibiotics and risk of kidney stones. Curr Opin Nephrol Hypertens. 2019;28(4):311-5. KRKA. Atazanavir - Summary of Product Characteristics. 2019. Available at: https://www.ema.europa.eu/en/documents/product-information/atazanavir-krka-epar-product-information_en.pdf. Last accessed: 25 May 2025 Grant MT et al. Ureteral obstruction due to radiolucent atazanavir ureteral stones. J Endourol Case Rep. 2017;3(1):152-4. de Lastours V et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68(8):1850-6. Hamada Y et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55(9):1262-9. Takhar J, Manchanda R. Nephrolithiasis on topiramate therapy. Can J Psychiatry. 2000;45(5):491-3. Pelzman DL et al. Urinary metabolic disturbances during topiramate use and their reversibility following drug cessation. Urology. 2022;165:139-43. Maalouf NM et al. Nephrolithiasis in topiramate users. Urol Res. 2011;39(4):303-7. Shen AL et al. Topiramate may not increase risk of urolithiasis: a nationwide population-based cohort study. Seizure. 2015;29:86-9. Cutroneo PM et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024;3:1323057. European Medicines Agency. Medicines under additional monitoring. 2023. Available at: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/medicines-under-additional-monitoring. Last accessed: 21 January 2024 Harpaz R et al. Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System. Clin Pharmacol Ther. 2013;93(6):539-46. Frent I et al. A description of acute renal failure and nephrolithiasis associated with sodium–glucose co-transporter 2 inhibitor use: a VigiBase study. Front Pharmacol. 2022;13:925805. Makunts T et al. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep. 2019;9(1):2282. Alshehri BJ, Shalabi HS. SGLT-2 inhibitors and their correlation with kidney stones. a systematic review. Journal of Health and Rehabilitation Research. 2024;4(2):282-90. Tasian GE et al. Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. Clin J Am Soc Nephrol. 2016;11(3):488-96. Matlaga BR et al. Drug-induced urinary calculi. Rev Urol. 2003;5(4):227-31. Daudon M t al. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs. 2018;78(2):163-201. Wang Z et al. Recent advances on the mechanisms of kidney stone formation (Review). Int J Mol Med. 2021;48(2):149. Khan SR, Canales BK. Proposal for pathogenesis-based treatment options to reduce calcium oxalate stone recurrence. Asian J Urol. 2023;10(3):246-57. Trifirò G, Crisafulli S. A new era of pharmacovigilance: future challenges and opportunities. Front Drug Saf Regul. 2022;2:866898. Faillie JL. Case–non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225-32.